(secondQuint)A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease.

 This study will enroll 150 moderately severe to severe Alzheimer's disease subjects.

 Subjects will be randomly assigned 1:1:1 to treatment with two different doses of bryostatin 1 or placebo.

 The primary analysis will take place after 12 weeks of treatment (7 doses).

.

 A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease@highlight

This is a randomized double-blind placebo-controlled study comparing different doses of bryostatin for the treatment of moderately severe to severe Alzheimer's disease.

 The study is 15 weeks in duration, including a safety and efficacy evaluation 30 days after the last dose of study drug.

